Diabetic Dyslipidemia: A Precision Framework for Risk-Based Lipid Management

Abstract

Atherogenic dyslipidemia refers to a specific pattern of blood lipid abnormalities that promotes atherosclerotic cardiovascular disease (ASCVD). It is defined by elevated triglycerides (TG ≥150 mg/dL), reduced high-density lipoprotein cholesterol (HDL-C <40 mg/dL in men, <50 mg/dL in women), elevated non-HDL-C (reflecting all ApoB-containing lipoprotein particles), and increased small, dense low-density lipoprotein cholesterol (sdLDL-C; even when LDL-C may be normal or near normal) on standard lipid panels (SLPs). Diabetic dyslipidemia is a subset of atherogenic dyslipidemia seen in individuals with diabetes mellitus (DM), diagnosed by elevated glucose (random ≥ 200 mg/dL, fasting ≥ 126 mg/dL, HbA1c ≥ 6.5%, or 2-hour OGTT ≥ 200 mg/dL). Insulin resistance (IR) is the most common underlying driver of this lipid phenotype and explains its frequent presence in type 2 diabetes (T2DM), pre-diabetes (PDM), obesity, metabolic syndrome (MetS), and polycystic ovarian syndrome (PCOS). Elevated triglycerides and low HDL-C are robust epidemiologic markers of future dysglycemia and ASCVD risk in IR states.

This SMART approach aims to enhance diagnosis and management of atherogenic dyslipidemia associated with IR and DM. It outlines a practical differential diagnosis with and without IR/DM, summarize current lipid management guidelines, and proposes a real-world, personalized treatment framework. Key clinical insights are also included to address common challenges in managing these patients.